David Cheishvili (He/Him)

Chief Innovation Officer, EpiMedTech Global
  • Singapore

About David Cheishvili

An epigenetics and molecular biology professional with experience in the academic, public, and private sectors. Holds a PhD in biochemistry and currently serves as Chief Innovation Officer at epiMedTech Global (Singapore) and as an affiliate member at McGill University (Canada)

Popular Content

Topics

Channels contributed to:

Behind the Paper

Recent Comments

Jun 13, 2023
Replying to Aoife Gahlawat

Great work, is this very specific to HCC? Have you tested other caner types`?

Thank you for your kind words and for your interest in our work. This high-throughput test has been specifically developed for the early detection of Hepatocellular Carcinoma (HCC). To ensure its specificity to HCC, the assay underwent testing on individuals with 15 different non-HCC cancers (Fig. 5, 6 and 7 of the manuscript). 

Details

Online Elsewhere